Diabetology and oncology meet in a network model: union is strength
Diabetes and cancer are increasingly common conditions, and the management of cancer patients with diabetes is often challenging. Diabetes in cancer patients poses several complex clinical issues, including which treatment is suitable to control hyperglycemia, how to better counteract glucocorticoid-induced hyperglycemia, and how to manage nutritional problems of cachectic patients and glucose variability linked to artificial nutrition. A key aspect to consider is the patients’ position on the trajectory of the oncologic disease, both to establish which level of glycemic control should be pursued and to decide the most suitable antidiabetic treatment to recommend. Endocrinologists are rarely involved in the management of patients with advanced cancer. Furthermore, lack of guidelines results in a “trial-and-error” approach, often with suboptimal disease management. Lastly, cancer survivors represent a frequently underestimated category of patients at higher cardiometabolic risk. A practical solution for these challenges lies in the implementation of care networks based on a close partnership and ongoing communication between oncologists, endocrinologists, and nutritionists, placing the patient at the center of the care process. At the same time, universities and scientific societies should play a key role in promoting research into areas of intersection of oncology and endocrinology, in raising awareness of common possibilities of primary and secondary prevention of metabolic and oncologic diseases, as well as specific challenges of managing diabetes and cancer, and proper training of health workers, while also supporting the shared implementation of effective management strategies.
KeywordsDiabetes Cancer Glucocorticoids Artificial nutrition Clinical management Cancer survivors
The authors hereby declare that the manuscript has not been published before, and it is not under consideration for publication anywhere else. Furthermore, its publication has been approved by all co-authors. All authors have contributed to the scientific work and therefore share collective responsibility and accountability for the results.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
- 27.World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. http://www.wcrf.org/sites/default/files/Second-Expert-Report.pdf. Accessed 22 Sept 2015
- 29.World Cancer Research Fund International. New frontiers in cancer research: the role of DIET, nutrition, body composition and physical activity—Guidelines for applicants and award recipients 2014–2015. http://www.wcrf.org/sites/default/files/Guidelines_WCRF_RGP_2014-5.pdf. Accessed 22 Sept 2015
- 32.August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors (2009) A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 33:472–500CrossRefPubMedGoogle Scholar
- 39.Genolet P, Petite C, Petignat PA (2012) Diabète cortico-induit, une entité fréquente sans prise en charge standardisée. Rev Med Suisse 8(800–802):804–805Google Scholar
- 41.Yuen KC, McDaniel PA, Riddle MC (2012) Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol (Oxf) 77:224–232. doi: 10.1111/j.1365-2265.2011.04242.x CrossRefGoogle Scholar
- 49.Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149. doi: 10.2337/dc14-2441 CrossRefPubMedGoogle Scholar
- 54.ESMO Handbook on Clinical Pharmacology of Anti-Cancer Agents. http://oncologypro.esmo.org/Publications/Handbooks/Clinical-Pharmacology-of-Anti-Cancer-Agents. Accessed 22 Sept 2015
- 56.Rugo HS, Pritchard KI, Gnant M et al (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25:808–815. doi: 10.1093/annonc/mdu009 CrossRefPubMedPubMedCentralGoogle Scholar
- 58.Weroha SJ, Haluska P (2012) The insulin-like growth factor system in cancer. Endocrinol Metab Clin N Am 41:335–350, vi. doi: 10.1016/j.ecl.2012.04.014
- 59.Howlader N, Noone AM, Krapcho M et al (2014) SEER cancer statistics review, 1975–2011, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2011/. Accessed 22 Sept 2015
- 62.Lipshultz SE, Adams MJ, Colan SD et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927–1995CrossRefPubMedGoogle Scholar
- 64.Lancellotti P, Nkomo VT, Badano LP et al (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26:1013–1032CrossRefPubMedGoogle Scholar
- 70.The Children’s Oncology Group (2013) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult. Version 4.0—October 2013. http://www.survivorshipguidelines.org. Accessed 22 Sept 2015